Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eletriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 9/20 | 1.00 |
| ▸ | HTR1D known ✓ | P28221 | 6/20 | 0.66 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 12/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eletriptan SCHEMBL26719 | 1.00 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL10083479 | 1.00 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL29414096 | 1.00 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL1556539 | 1.00 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL4431798 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL3713443 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL4233264 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL1068516 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL29244076 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL317370 | 0.99 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100285075-A1 | Novel Hemioxalate Salt of Eletriptan | ACTAVIS GROUP PTC EHF (IS) | 2010-11-11 | — | — | US | claimed |
| EP-0592438-B1 | INDOLE DERIVATIVES | PFIZER (US) | 1997-08-27 | — | — | EP | claimed |
| US-5618834-A | Indole derivatives in the treatment of emesis | PFIZER INC. (US) | 1997-04-08 | — | — | US | claimed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | claimed |
| EP-0714659-A2 | Indole derivatives in the treatment of emesis | Pfizer Limited (GB) | 1996-06-05 | — | — | EP | claimed |
| EP-0592438-A1 | INDOLE DERIVATIVES. | PFIZER (US) | 1994-04-20 | — | — | EP | claimed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | claimed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4335504-A2 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma ApS (DK) | 2024-03-13 | — | — | EP | disclosed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | disclosed |
| US-11478476-B2 | Use of buspirone metabolites | CONTERA PHARMA APS (DK) | 2022-10-25 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0714659-A2 | Indole derivatives in the treatment of emesis | Pfizer Limited (GB) | 1996-06-05 | — | — | EP | disclosed |
| EP-0592438-A1 | INDOLE DERIVATIVES. | PFIZER (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | HTR1B 4261/4885HTR1D 4430/4885HTR1F 3444/4885 |
| US-20100285075-A1 | Novel Hemioxalate Salt of Eletriptan | HAAO, HPD, HNMT | HTR1B 1083/4885HTR1D 959/4885HTR1F 1526/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | HTR1B 4261/4885HTR1D 4430/4885HTR1F 3444/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | HTR1B 3999/4885HTR1D 4159/4885HTR1F 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.